Contract researchHTA, CEA

HTA – Health Technology Assessment

 

IBA MU has long-term experience in the field of health technology assessment (HTA) and cost-effectiveness analysis (CEA) due to its participation in many clinical projects. The institute is involved in activities of the University Centre for Epidemiology and Pharmacoeconomy (UCE) in cooperation with the Institute of Pharmacology at the Faculty of Medicine, MU.

UCEP was established with the objective to implement innovative strategies in research and education in the fields of pharmacoepidemiology and pharmacoeconomy, and to provide all relevant partners (health care payers, state authorities, professional medical societies, etc.) with a comprehensive and professional service based on the cooperation of a multidisciplinary team.

Some outputs on HTA and CEA were published in peer-reviewed medical journals and document vast experience of IBA MU and its partners, particularly in the fields of oncology, cardiology, ophthalmology, and other specialties. A list of selected publications is given below.

Contact: Michal Burger, M.Sc.

Reference

  • Dušek, L., Schwarz, D., Burger, M., Blaha, M., Kožený, P., Němeček, K., Brabec, P., Klimeš, D., Májek, O., Pavlík, T. Methodology of data collection and evaluation of treatment with highly innovative drugs. 2013. Published at http://www.nrc.cz/vilp/index.htm.
  • Říhová, B., Pařenica, J., Jarkovský, J., Miklík, R., Šulcová, A., Littnerová, S., Felšőci, M., Kala, P, Špinar, J. Cardiology department hospitalization costs in patients with acute heart failure vary according to the etiology of the acute heart failure: Data from the AHEAD Core registry 2005–2009. Cor et Vasa, 2013; 55(1): e7-e14.
  • Studnička, J., Říhová, B., Rencová, E., Rozsíval, P., Dubská, Z., Chrapek, O., Kolář, P., Kandrnal, V., Demlová, R., Pitrová, Š., Řehák, J. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice. Ophthalmologica, 2013; 230(1): 34-42.
  • Dhaifalah, I., Májek, O. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic. Česká gynekologie, 2012; 77(1): 39-51.
  • Büchler, T., Nohejlová Medková, A., Kupec, M., Blaha, M., Pavlík, T., Dušek, L., Abrahámová, J. Cost Analysis of XELOX and FOLFOX-4 Chemotherapy Regimens for Colorectal Carcinoma. Klinická onkologie, 2012; 25(6): 440-444.
  • Doležal, T., Říhová, B., Demlová, R., Dušek, L. Principles of pharmacoeconomic evaluation - global trends and Czech reality. Postgraduální medicína, 2011; 13(8): 825-827.
  • Dušek, L., Kandrnal, V., Brabec, P., Demlová, R., Koptíková, J., Gregor, J., Vyzula, R., Fínek, J. Methodical aspects of cost-effectiveness evaluation of cancer care in terms of availability and clinical data analysis. Postgraduální medicína, 2011; 13(8): 836-844.
  • Májek, O., Dušek, L., Suchánek, Š., Demlová, R., Kožený, P., Suchý, M., Zavoral, M. Cost-effectiveness of colorectal cancer screening: an educational overview and programme efficacy modeling in the Czech Republic. Postgraduální medicína, 2011; 13(8): 854-862.
  • Salaj, P., Penka, M., Smejkal, P., Geierová, V., Ovesná, P., Dušek, L. Economic comparison of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate using the hemophilia registries of the Czech Republic. Haemophilia, 2010; 16(S4): 59.
  • Ondráčková, B., Miklík, R., Pařenica, J., Špinar, J., Pavlík, T. Hospitalization costs and length of stay in patient with acute heart failure. Farmakoekonomika, 2007; 2: 50-55.